Language On SRHR, Drug Development Costs Remain Unresolved In U.N. Draft UHC Declaration

Health Policy Watch: Drug R&D, Sexual & Reproductive Health Scrutinized In Draft UHC Declaration
“Disclosure of costs for drug research and development (R&D) and ‘alternative financing mechanisms’ for new health products remain outstanding points to be resolved by countries in finalizing a draft United Nations General Assembly political declaration on universal health coverage (UHC). A final draft of the declaration had been expected [last] week, but as of Friday afternoon, language on sexual and reproductive health and rights (SRHR) and drug development issues appeared to be unresolved in the draft text, obtained by Health Policy Watch. … [The SRHR] language has been controversial in light of opposition by the U.S. as well as some developing countries to any references to sexual or reproductive health that could imply access to abortion. Additionally, the Group of 77 (G77), a coalition of 134 developing nations, have experienced sharp differences of opinion on both access to abortion and contraception, and members have decided not to vote as a bloc on the issue, sources said…” (Branigan, 7/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.